Identify how definitional drift impacts market sizing and target lists: Discover why identical claims datasets can yield multi-million patient swings in cohort size, and how unexamined code choices misallocate commercial spend and field resources.
Evaluate data quality and denominator stability before building forecasts: Learn what to ask data partners, why unprojected claims provide a more reliable baseline than statistical projections, and how longitudinal eligibility data removes ambiguity.
Apply a 4-part framework to generate verifiable, purpose-driven evidence: Master the core requirements needed to produce real-world evidence that withstands payer and regulatory scrutiny, while leveraging initiatives like PurpleLab CARES to support community research.
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.